Principal Financial Group Inc. Lowers Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Principal Financial Group Inc. lowered its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 69.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,513 shares of the company’s stock after selling 28,706 shares during the period. Principal Financial Group Inc.’s holdings in ImmunityBio were worth $47,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently modified their holdings of IBRX. Victory Capital Management Inc. grew its holdings in ImmunityBio by 16.0% in the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock valued at $126,000 after purchasing an additional 2,746 shares during the last quarter. Wealth Effects LLC boosted its position in ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock worth $337,000 after acquiring an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of ImmunityBio by 8.4% during the third quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock worth $178,000 after purchasing an additional 3,722 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of ImmunityBio by 3.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company’s stock valued at $667,000 after purchasing an additional 4,533 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in ImmunityBio by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of ImmunityBio in a report on Thursday, November 21st. Finally, Piper Sandler cut their target price on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research report on Monday, August 19th.

ImmunityBio Trading Up 1.6 %

Shares of ImmunityBio stock opened at $5.12 on Wednesday. ImmunityBio, Inc. has a twelve month low of $3.10 and a twelve month high of $10.53. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -5.57 and a beta of 0.99. The company has a fifty day moving average price of $4.30 and a 200 day moving average price of $5.12.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.